Compounds for the modulation of PPARγ activity

1. A compound having the formula:

wherein

Ar 1 is unsubstituted 3-quinolinyl;

X is —O—;

Y is —NH—S(O) 2 —;

R 1 is halogen;

R 2 is a phenyl group having from 0 to 3 substituents, wherein the substituent is halogen; and

R 3 is halogen;

or a pharmaceutically acceptable salt of the compound.

2. A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:

wherein

Ar 1 is unsubstituted 3-quinolinyl;

X is —O—;

Y is —NH—S(O) 2 —;

R 1 is halogen;

R 2 is a phenyl group having from 0 to 3 substituents, wherein the substituent is halogen; and

R 3 is halogen;

or a pharmaceutically acceptable salt of the compound.

3. A method for treating a condition mediated by PPARγ in a host, said method comprising administering to said host an efficacious amount of a compound having the formula:

wherein

Ar 1 is unsubstituted 3-quinolinyl;

X is —O—;

Y is —NH—S(O) 2 —;

R 1 is halogen;

R 2 is a phenyl group having from 0 to 3 substituents, wherein the substituent is halogen; and

R 3 is halogen;

or a pharmaceutically acceptable salt of the compound.

4. A method in accordance with claim 3 , wherein said condition is selected from the group consisting of non-insulin-dependent diabetes mellitus, obesity, hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, and inflammatory conditions.